Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: a beautiful day in the sector’s neighborhood

February 15, 2022 5:12pm

Coming off a volatile Monday trading session

Pre-open Indications: 12 HIT and 3 MISS

News: Intellia Therapeutics (NTLA +$8.21) announced a licensing and collaboration agreement with ONK Therapeutics Ltd., developing engineered natural killer (NK) cell therapies to cure patients with cancer.

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?

The Dow closed UP +422.67 points (+1.22%); the S&P closed UP +69.40 points (+1.58%) while the Nasdaq closed UP +348.84 points (+2.53%)

Henry’omics:

Indexes rose for the first day in four (4) on Tuesday after Russia appeared to be backing away from an immediate invasion of Ukraine, cooling geopolitical tensions that have knocked the stock market down the last three days.

Economic Data Docket: The producer price index, which measures final-demand goods and services, increased 1% for the month, against the Dow Jones estimate for 0.5%. Over the past 12 months the gauge rose an unadjusted 9.7%. Excluding food, energy and trade services, co-called core PPI increased 0.9% for the month, topping the 0.4% estimate.

News: full release on NTLA … https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-onk-therapeutics-announce-collaboration-advance

RegMed Investors’ (RMi) pre-open: “a tailwind of sharply higher futures due to past headlines following huge pull-backs” … https://www.regmedinvestors.com/articles/12301

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

Tuesday opened positive at 29 up/3 downs, 2 flats and 1 acquired, stayed positive at the mid-day at 30/1, 3 flats and 1 acquired, ending with a positive close of 31/1, 2 flats and 1 acquired;
Monday opened negative at 11 up/17 downs, 6 flats and 1 acquired, stayed negative at the mid-day at 7/26, 1 flat and 1 acquired, ending with a negative close of 4/28, 2 flats and 1 acquired;

Pre-open indications: 12 Hit < Adverum Biotechnologies (ADVM +$0.03), CRISPR Therapeutics (CRSP +$2.36), Editas Medicine (EDIT +$0.86), Ionis Pharmaceuticals (IONS +$1.07), MiMedx (MDXG +$0.57), Intellia Therapeutics (NTLA +$8.21), Pluristem (PSTI +$0.13), UniQure NV (QURE +$0.48), ReNeuron (RENE.L +$0.00 with 116,715 shares traded), Solid Biosciences (SLDB +$0.02); SELL: Applied Genetic Technologies (AGTC -$0.24), Biostage (BSTG -$0.00 with 200 shares traded)> 3 MISS < Brainstorm Cell Therapeutics (BCLI +$0.09), Sage Therapeutics (SAGE +$1.21), Voyager Therapeutics (VYGR +$0.11)>

The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares trading flat again with 200 shares traded after Monday’s flat with 1,899 shares traded after

Last Friday’s -$0.02 with 1,739 shares traded after Thursday’s +$0.60 with 2,841 shares traded after Wednesday’s down -$0.61 (was as low as -$1.09) with 4,030 shares traded after Tuesday’s +$0.05 with 1,293 shares traded after Monday’s +$0.55 with 2,311 shares traded,

The previous Friday’s +$0.22 with 305 shares traded, Thursday’s flat ($0.00) with 3 shares traded, Wednesday’s down -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded after last Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and the previous Tuesday’s +$0.31 with 2,794 shares traded.

Key Metrics:

Tuesday - Sector volume was LOW with 4 of the 32-upside having higher than the 3-month average volume with LOW volume of 1 of 1-downside having higher than the 3-month average volume
Monday - Sector volume was LOW with 2 of the 4-upside having higher than the 3-month average volume with LOW volume of 5 of 28-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Tuesday the IBB closed up +1.80% and XBI closed up +4.17%
Monday the IBB closed down -1.84% and XBI closed down -1.65%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Tuesday was down -2.63 points or -9.28% at 25.70
Monday was up +0.97 points or +3.55% at 28.33

Jumping with share pricing momentum (10 of 31):

Intellia Therapeutics (NTLA +$8.21 after Monday’s -$1.11),
Alnylam Pharmaceuticals (ALNY +$4.64 after Monday’s -$2.10),
CRISPR Therapeutic (CRSP +$2.36 after Monday’s -$0.79),
Ultragenyx (RARE +$2.30 after Monday’s -$1.66),
Regenxbio (RGNX +$1.86),
Global Blood Therapeutics (GBT +$1.58 after Monday’s -$0.35),
Vericel (VCEL +$1.54 after Monday’s +$0.32),
Fate Therapeutics (FATE +$1.49 after Monday’s -$1.41),
Sage Therapeutics (SAGE +$1.21 after Monday’s -$0.75),
Ionis Pharmaceuticals (IONS +$1.07),

Hammered in today’s market (1 of 1):

Applied Genetic Technologies (AGTC -$0.24),

Closing Flat:

2 – Biostage (BSTG), ReNeuron (RENE.L), and 1 - -Stemline Therapeutics (STML) – acquired

February, Q1/2022:

Tuesday closed positive with 31 incliners, 1 decliner, 2 flat and 1 acquired
Monday (2/14) closed negative with 4 incliners, 28 decliners, 2 flats and 1 acquired
Friday closed negative with 3 incliner, 32 decliners and 1 acquired
Thursday closed negative with 5 incliner, 28 decliners, 1 flat and 1 acquired

The BOTTOM LINE: Back in the game of forward and upward share pricing motion.

The sector jumped as positive geopolitical headlines redefined the risk parameters of equites and our universe of cell and gene therapy stocks.

The race to the weekend …

Tuesday’s “sprinters” were Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Ultragenyx (RARE) with only 1 loser Applied Genetic technologies (AGTC) with ReNeuron (RENE.L) and Biostage (BSTG) flat

Monday closed down with just a few ups … Vericel (VCEL), Voyager therapeutics (VYGR), uniQure NV (QURE) and Caladrius Biosciences (CLBS) while the downs were numbered at 28.

Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.

AxoGen AXGN) –Tuesday, 2/22

Vericel (VCEL) –Thursday, 2/24,
MiMedx (MDXG), Monday, 2/28
Athersys (ATHX), Tuesday, 3/15

WHY do I keep analyzing Biostage (BSTG): I WAS there to experience the lack of investor prerogatives and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.